Real World Evidence

C-suite leaders in pharmaceutical companies increasingly view Real World Evidence (RWE) as strategically important. RWE enables R&D organisations to prioritise their pipeline investments more effectively, better understand underlying causes of disease and identify opportunities for indication expansion and business development.

In the sixth episode of Life Sciences Connect, we explore the role of Real World Evidence in providing insights into existing diagnostic and treatment pathways, identifying unmet need and demonstrating the clinical and economic impact of interventions within the healthcare system.

This episode is led by our host Karen Taylor. Karen is joined by Meri Petrovsca, the Knowledge Management Director at AstraZeneca and Seb Burnett, the General Manager of ConvergeHEALTH by Deloitte Europe.

This episode explores:

• The impact of RWE on biopharma companies
• Implementing knowledge management to maximise Real World Data (RWD)
• The role of skills and talent in maximising value from RWD and the challenges the industry faces in accessing such talent